Abstract: A use of a compound or a medicinal derivative thereof in inhibiting calcium/calmodulin-dependent protein kinase type II gamma (CaMK2?) protein activity is provided, and belongs to the technical field of protein inhibitors. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe, and stable. Moreover, the compound has a strong binding force with human-derived CaMK2? protein and mouse-derived CaMK2? protein, and binding constants are KD=2.54×10?5M and KD=6.84×10?5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.

Abstract: A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided, and belongs to the field of protein inhibitory medicine technology. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as 1.029E-5M and 1.033E-5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.

Abstract: An application of an adrenoceptor beta 1 (ADRB1) active inhibitor as or in preparing a preparation for treating psoriasis is provided and belongs to technical field of dermatologic drugs. The ADRB1 activity inhibitor (such as acebutolol hydrochloride, abbreviated ACE) is applied to the treatment of body psoriasis, which can effectively inhibit the increase of norepinephrine caused by abnormal activation of skin sympathetic nerve and stimulate ??T cells to secrete IL-17, thereby reducing IL-17-mediated immune response in psoriatic lesions and achieving the effect of treating psoriasis.

Abstract: An application method of a vascular endothelial growth factor receptor (VEGFR) gene expression inhibitor in preparing a preparation or taken as a preparation for treating psoriasis is provided and belongs to the field of drugs for skin diseases. Narrow-band ultraviolet B (NBUVB) radiation effectively inhibits an abnormal expression of a renin-angiotensin system guanyl releasing protein 1 (RASGRP1) gene in skin T-lymphocytes, thereby inhibiting the T-lymphocytes generating interleukin-17 (IL-17), and thus effectively alleviating IL-17-mediated immune response of the psoriasis in skin sites to achieve an effect of treating the psoriasis.

Abstract: A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided, and belongs to the field of protein inhibitory medicine technology. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as 1.029E-5M and 1.033E-5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.

Abstract: An application method of a preparation for inhibiting calcium/calmodulin-dependent protein kinase type II gamma (CAMK2G) expression in preparation of a medicine for treating psoriasis is provided and belongs to the field of psoriasis medicine technologies. The preparation can effectively inhibit the abnormal activation of CAMK2G in the skin sympathetic nerves to stimulate interleukin-17 (IL-17) secretion of ?? T cells, so as to reduce the immune response mediated by IL-17 in psoriatic skin and achieve the effect of treating psoriasis. It can also reduce production of neutrophil NETs in a circulatory system and inhibit aggravation of the disease, so as to have the effect of treating immune deficiency diseases.

Abstract: The invention relates to the field of pharmaceutical technology for treating skin diseases, in particular, to the use of an agent in preparation of a medicine for treating/inhibiting psoriasis. The agent in the invention is aimed at the inhibition or promotion of a relevant signal in dsDNA-AIM2-Caspase1-IL1b signaling pathway, thus realizing the purpose of treating/inhibiting psoriasis. The agent can effectively inhibit the immune response caused by the inflammasome when used in the medicine for treating/inhibiting psoriasis, thus realizing the therapeutic effect on psoriasis and autoimmune diseases. The agent can also promote the inflammasome response, enhance the body's immune response, thus realizing the therapeutic effect on immunodeficiency diseases.

Abstract: The invention belongs to the field of medical information technology, and specifically relates to an evaluation system for evaluating psoriasis and use thereof. The evaluation system includes: a data acquisition module for acquiring the dsDNA content of a serum sample to be detected, a data analysis module for evaluating psoriasis based on the dsDNA content, and a data output module for outputting results according to the evaluated psoriasis. When the serum sample to be detected is a serum sample without phenotype and the dsDNA content is ?1.11 ng/ml, the output would be: abnormal and extremely high risk. The sensitivity of the evaluation system is 61.6% and the specificity is 74.8%. Compared with other types of psoriasis-related methods and apparatuses, the sensitivity and specificity have obvious advantages.

Abstract: An application of CaMK4 as a target in preparation of medicines for preventing and treating psoriasis and an application of a CaMK4 inhibitor in preparation of medicines for preventing and treating psoriasis are provided. The expressions of CaMK4 in skin lesions of patients with psoriasis and IMQ induced skin lesions of mice with psoriasis are detected, and the results show that CaMK4 is positively correlated with psoriasis development. CaMK4 is expressed not only in immune cells, but also in keratinocytes. Moreover, IL-10 and the CaMK4 inhibitor can reduce psoriasiform inflammation induced by IMQ in mice. It shows that CaMK4 can be used as a new target in the preparation of medicines for prevention and treatment of psoriasis.